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Accept the failures as opportunities for growth,
get excited by the successes. 
Enjoy the journey.
- Raymond Floyd -
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Abstract  
Germ cell tumors occur both in the gonads of both sexes and in extra-gonadal sites during ado-
lescence and early adulthood. Malignant ovarian germ cell tumors are rare neoplasms account-
ing for less than 5 % of all cases of ovarian malignancy. Testicular cancer, in contrast, is the 
most common malignancy among young males. Most patients survive the disease. Prognostic 
factors of gonadal germ cell tumors include histological classification, clinical stage, size of the 
primary tumor and residua, and levels of tumor markers. 
Germ cell tumors most likely develop from early primordial germ cells; oocytes or gonocytes. 
In the testis a common tumor precursor, the carcinoma in situ (CIS) cell, was recognized in 
1972 by Skakkebaek. Despite their common origin, germ cell tumors include heterogeneous 
histological subgroups. The most common subgroup includes germinomas (ovarian dysgermi-
noma and testicular seminoma); other subgroups are yolk sac tumors, embryonal carcinomas, 
immature teratomas and mixed tumors. Factors behind their differential development are still 
poorly known. 
Pathohistological diagnosis of germ cell tumors is based on histological evaluation and distinc-
tive immunohistological markers. However, differential diagnosis is challenging, as some of 
the tumors may be confused with other tumor types. Correct knowledge of the histological type 
of the tumor is essential, as prognosis and treatment are dependent on the tumor type.
The serum tumor markers α-fetoprotein (AFP) and the β-subunit of human chorionic gonado-
tropin (hCGβ) are used in diagnosis and follow-up. Concentrations of AFP are elevated in yolk 
sac tumors whereas those of hCGβ are elevated in choriocarcinomas. However, only a subset 
of gonadal germ cell tumors express these serum markers. Measurements of carcinoma antigen 
125 (CA 125) is used in diagnosis, prognosis and follow-up of ovarian epithelial tumors. How-
ever, its value in the prognosis of ovarian germ cell tumors is unknown.
The peak incidence of malignant ovarian germ cell tumors occurs soon after puberty. Thus, 
gonadal steroids have been speculated to play a role in tumor development and progression. 
Estrogen signalling is mediated via estrogen receptors (ERs) α and β. These belong to the 
nuclear receptor superfamily, and various co-regulators modify their actions. The co-activator 
small nuclear ring finger protein 4 (SNURF/RNF4) is one of these co-regulators. In testicular 
germ cell tumors ERβ and SNURF are down-regulated. However, the role of ERs in ovarian 
germ cell tumors is unknown. 
 
Given that the origin of germ cell tumors is most likely primordial germ cells, pluripotent 
factors are of interest in the development of these tumors. The transcription factor Oct-3/4 
(POU5F1) is expressed in embryonic stem cells and primordial germ cells and it is involved in 
maintenance of pluripotency. Activator protein-2 gamma (AP-2γ) is required for early post-im-
plantation development. Both Oct-3/4 and AP-2γ are expressed in fetal germ cells as well as in 
testicular CIS cells. Estradiol induces AP-2γ expression in prostate cancer cells. Thus, estradiol 
signalling might regulate AP-2γ expression in germ cell tumors. 
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Many genes are involved in germ cell and gonadal development and may thus play a role in 
germ cell tumorigenesis. Of the six GATA transcription factors, GATA-4 and GATA-6 are 
involved in gonadal differentiation and function. In addition, GATA-4 and -6 as well as their 
downstream target genes (HNF-4, BMP-2, Ihh) are essential for normal yolk sac development. 
GATA-4 and its interaction with cofactor FOG-2 are essential for appropriate GATA-4 func-
tion in testis development. In addition to GATA-4, its target genes, including SF-1, AMH and 
INH-α, are involved in normal testicular differentiation, development and function.
The purpose of this study was to define novel diagnostic and prognostic factors associated with 
malignant gonadal germ cell tumors. Another aim was to shed further light on the molecular 
mechanisms regulating gonadal germ cell tumorigenesis and differentiation by studying the 
roles of GATA transcription factors, pluripotent factors Oct-3/4 and AP-2γ, and estrogen recep-
tors.
In the present study, elevated preoperative levels of serum CA 125 were associated with poor 
outcome in malignant ovarian germ cell tumor patients. In addition, age above 30 years and 
residual tumor were associated with more adverse outcomes.
In the fetal testis, GATA-4 was expressed in a subpopulation of early fetal gonocytes at the 15th 
gestational week. However, GATA-4 expression was down-regulated during further embryo-
genesis and absent in adult testicular germ cells. In testicular CIS cells GATA-4 was heteroge-
neously expressed. Thus, GATA-4 expression in early fetal germ cells and in testicular tumor 
precursors provides evidence for the fetal origin of testicular germ cell tumors. The essential 
endodermal gene GATA-4 was expressed in ovarian dysgerminomas and in testicular semino-
mas. In addition, their endodermal (HNF-4, BMP-2, Ihh) and gonadal (SF-1) target genes were 
expressed in these tumors. Thus, expression of GATA-4 and its target genes displays evidence 
for a functional role of GATA-4 in the germinoma subgroup of germ cell tumors. 
In the ovary, expression of AP-2γ and Oct-3/4 was positive in most of the dysgerminomas, 
whereas the majority of other subtypes were negative. Thus, AP-2γ and Oct-3/4 are of value 
in differential diagnosis of ovarian germ cell tumors. In addition, their dysgerminoma-specific 
expression provides evidence for the primordial nature of this subgroup of germ cell tumors. 
All evaluated malignant ovarian germ cell tumor subtypes (dysgerminomas, yolk sac tumors, 
immature teratomas) expressed both ERα and ERβ, and their co-activator SNURF. The role of 
estrogen regulation of dysgerminomas was studied by using a human germinoma-derived cell 
line (NCC-IT). Stimulation with estradiol significantly increased the expression of both ERs 
and SNURF in a dose- and time-related manner. In addition, the effect of estradiol was counter-
acted by an anti-estrogen (ICI 182,780).  
In conclusion, this study revealed the prognostic value of CA-125 in malignant ovarian 
germ cell tumors. In addition, several novel markers for histological diagnosis were defined 
(GATA-4, GATA-6, AP-2γ, Oct-3/4). Moreover, these factors may be involved in gonadal 
germ cell tumorigenesis and differentiation. In early fetal development the transcription fac-
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tor GATA-4 was expressed in gonocytes in addition to CIS cells, and may thus have a role in 
fetal testicular CIS development. In addition to testicular CIS cells, GATA-4 was expressed in 
both types of gonadal germinoma: thus it may play a role in the differentiation of these tumor 
subtypes. In addition to  GATA-4, the pluripotent factors Oct-3/4 and AP-2γ were expressed in 
dysgerminomas: thus they could be used in differential diagnosis. This study provided evidence 
of steroid hormone regulation in ovarian germ cell tumors. MOGCTs expressed estrogen recep-
tors and their co-receptor SNURF. In addition, ER expression was up-regulated by estradiol 
stimulation. Thus, the gonadal steroid hormone burst in puberty may play a role in germ cell 
tumor development in the ovary.
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AFP  Alpha fetoprotein
AMH/MIS Antimüllerian Hormone/Müllerian-Inhibiting Substance
AP-2γ  Activator protein 2 gamma
BMP  Bone morphogenic protein
ERα  Estrogen Receptor alpha
ERβ  Estrogen Receptor beta
ES cell  Embryonic stem cell
CA 125  Carcinoma antigen 125
CIS  Carcinoma in situ
DAX  Dosage-dependent sex reversal; 
  Adrenal hypoplasia congenital; X-chromosome
FOG-2  Friend of GATA-2
FOXL2   Forkhead box L2
hCGβ  β-subunit of human chorionic gonadotropin
HNF-4  Hepatocyte nuclear factor 4
Ihh  Indian hedgehog 
INHα  Inhibin-α
iPS cell  Induced pluripotent stem cells
MOGCT Malignant ovarian germ cell tumor
Oct-3/4  Octamer binding protein
PGC  Primordial germ cell 
PLAP  Placental-like alkaline phosphatase
RSPO1  R-spondin 1
SF-1  Steroidogenic factor 1
siRNA  Small interfering RNA
SNURF  Small nuclear ring finger protein
SRY  Sex determining region of Y-chromosome
TDS  Testicular dysgenesis syndrome
TGCT  Testicular germ cell tumor
WT1  Wilm’s tumor factor 1
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Introduction
At the beginning of a new life a sperm cell fuses with an oocyte. This fusion of germ cells 
creates a population of dividing cells. These dividing embryonic cells form a population – the 
inner cell mass of the blastocyst. These cells are pluripotent, with the capability of forming all 
the cell types within the human body. As embryogenesis progresses these undifferentiated cells 
lose their pluripotency and differentiate into specific cells forming the various tissues and or-
gans. However, germ cells maintain their pluripotency, and form new sperm cells and oocytes 
with the potential to create new life once again. 
The primordial gonad, in which the germ cells develop, is unique among all organs because 
of its bi-potential nature during the first weeks of embryogenesis. Both the male and female 
gonads develop from the same uniform primordial gonad.  In humans sex determination is 
genetically regulated by the presence of the Y chromosome in the male. The secondary sex 
characteristics develop through orchestrated complex cascades leading to gonadal differentia-
tion either into a testis or an ovary. Initiation of the human male pathway depends on gonadal 
expression of the Y-linked gene, SRY. Ten percent of people showing partial or complete sex 
reversal carry mutations in SRY (Hawkins et al. 1992b).
Tumors arising from a germ cell lineage are called germ cell tumors. While these tumors de-
velop during early embryogensis from primordial germ cells, pluripotent factors play a key role 
in their formation. Prolonged expression of pluripotent factors (Oct-3/4, AP-2) in germ cells 
may lead to maturation defects of these cells and activation of growth factors, which in turn 
promote cell proliferation. 
The aim of the present work was to elucidate the molecular mechanisms behind germ cell 
tumor formation and differentiation. Identification of the factors responsible for the survival 
of primordial germ cells may also be a crucial for understanding ovarian folliculogenesis and 
testicular spermatogenesis. Work in the field of germ cell tumors is challenging, as these tu-
mors are rare, but at the same time they are fascinating because of their close relationship with 
pluripotent stem cells. 
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Review of the Literature 
1. Germ cells
1.1 Inner cell mass and embryonic stem cells
Pluripotency refers to the ability to generate all differentiation lineages, whereas self-renewal is 
described as infinite cell division maintaining stem cell characteristics. Self-renewal and pluri-
potency are characteristics of embryonic cells. Dividing embryonic cells form a morula at the 
16-cell stage. This further develops into a blastocyst, where the inner cell mass (ICM) is sur-
rounded by trophoectoderm cells (Figure 1). Embryonic stem cells (ES cells) are derived from 
the ICM population, with pluripotent and self-renewing characteristics. They are able to gener-
ate all differentiated cell lineages; endodermal, mesodermal and ectodermal. Recently even 
germ cells have been derived from mouse and human ES cells (Hubner et al. 2003, Toyooka et 
al. 2003, Clark et al. 2004).
1.2 Factors essential for maintenance of pluripotency and self-renewal
Pluripotency is maintained in embryonic stem cells by the actions of various genes. OCT-
3/4(POU5F1), NANOG and SOX2 are factors regulating the maintenance of pluripotency 
in ES cells (Niwa et al. 2000, Mitsui et al. 2003). Moreover, OCT-3/4, in addition to KLF4, 
C-MYC, and SOX2, is essential in generating induced pluripotent stem cells (iPS cells) from 
mouse and human terminally differentiated cells (Takahashi et al. 2007, Lowry et al. 2008, 
Nakagawa et al. 2008). iPS cells are similar to ES cells in morphology, proliferation and pluri-
potency.  They show enormous promise for stem cell research and clinical therapeutics without 
the ethical and legal issues associated with embryonic stem cells. These cells have the potential 
to generate patient-specific cell types for cell replacement therapies. Potential target cells in-
clude pancreatic beta cells in cases of diabetes, myocardial cells after myocardial infarction and 
motor neurons in cases of spinal cord injuries. In addition to various cell types even adult mice 
have been generated from iPS cells (Boland et al. 2009).
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Figure 1. A–G. Development and migration of primordial germ cells. A. A fertilized embryo has formed a 
16-cell morula by day 4 after fertilization. B. By the 5th day after fertilization the inner cell mass is visible, 
surrounded by trophoblasts. C. - D. On the 9th day the bi-laminar germ disc is composed of epiblast and 
hypoblast (gray cells) and the amniotic cavity is forming within the epiblast (white cells). E. Primordial germ 
cells (black circles) originate within the epiblast during the 2nd week of development. F. Primordial germ cells 
migrate into the yolk sac at 4 to 6 weeks of development and (G) into the dorsal body wall at 6 to 12 weeks, 
inducing the formation of genital ridges. Modified from Larsen (1998).
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The protein OCT-3/4 belongs to the subgroup of octamer-binding proteins, which bind by 
the POU domain to the promoter and enhancer regions of various genes. Human OCT-3/4 is 
encoded by a homeobox-containing gene, POU5F, which is located on chromosome 6. During 
early embryogenesis OCT-3/4 is highly expressed in the ICM (Hansis et al. 2000), being essen-
tial for ES cell self-renewal. Loss of Oct-3/4 is lethal in mice because of lack of ICM formation 
(Nichols et al. 1998). Later in development OCT-3/4 is present in early primordial germ cells 
(PGCs), gonocytes and oogonia (Scholer et al. 1989, Rajpert-De Meyts et al. 2004). One of the 
putative target genes of OCT-3/4 is the stem cell-specific growth factor FGF-4, which is associ-
ated with human non-seminomatous testicular tumors (Suzuki et al. 2001, Wang et al. 2003). 
In ovarian germ cell tumors, OCT-3/4 is expressed in dysgerminomas, gonadoblastomas and in 
some yolk sac tumors (Hoei-Hansen et al. 2007). In addition, testicular seminomas, embryo-
nal carcinomas, teratomas, yolk sac tumors and carcinoma in situ (CIS) also express OCT-3/4 
(Hoei-Hansen et al. 2007).
 
Members of the DNA-binding transcription factor AP-2 family (AP-2α -β, -γ) play important 
roles in the development and differentiation of the neural tube, neural crest, skin, heart and 
urogenital tissues (Hilger-Eversheim et al. 2000). Activator protein-2γ is coded by the TFAP2C 
gene, located on chromosome 20, and it is required for early post-implantation development 
(Auman et al. 2002). In mice, loss of Ap-2γ is lethal as a result of malformation of extraembry-
onic tissues (Auman et al. 2002). 
In human embryogenesis AP-2γ has a role in germ cell development (Pauls et al. 2005). In fetal 
ovary, AP-2γ is expressed in oogonia from the 9th week, but it is not expressed later in oocytes 
(Hoei-Hansen et al. 2004) (Table 1). In fetal testis AP-2γ is expressed in gonocytes from the 
10th until the 22nd week of gestation (Hoei-Hansen et al. 2004) (Table 2). However, it is not de-
tected in spermatogonia of adult testes. In germ cell tumors AP-2γ has been detected in ovarian 
dysgerminomas and gonadoblastomas (Hoei-Hansen et al. 2007). Moreover, testicular CIS and 
seminomas (Pauls et al. 2005) as well as embryonal carcinomas, gonadoblastomas and to lesser 
extent teratomas express AP-2γ (Hoei-Hansen et al. 2004). In addition, AP-2γ is associated 
with other forms of neoplasia, particularly breast cancer but also with advanced stage epithelial 
ovarian cancer (Odegaard et al. 2006). One of the gonadal target genes for AP-2γ is c-KIT, a 
tyrosine kinase receptor for stem cell factor. C-KIT is involved in the migration of PGCs (Mo-
lyneaux et al. 2004). Mutations of c-KIT are involved in ovarian dysgerminomas as well as in 
bilateral testicular seminomas (Looijenga et al. 2003, Hoei-Hansen et al. 2007). 
Activator protein-2γ is regulated by the estrogen signalling pathway, as shown by induction 
of AP-2γ expression in breast tumor cells by estrogens (Orso et al. 2004). In addition, AP-2γ 
regulates the transcription of ERβ in prostate cancer cells by transactivating the ERβ promoter 
(Zhang et al. 2007). Thus, AP-2γ expression may also be hypothesized to be regulated by estro-
gens in germ cell tumors.   
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Table 1. Expression of selected proteins involved in female germ cell development  
Primordial germ cell Oogonia Oocytes
PLAP + + +/-
c-Kit + + +
Oct-3/4 + + +
AP-2γ + + -
ER + + +
PLAP; placental-like alkaline phosphatase, c-KIT; stem cell factor, ER; estrogen receptor.
Table 2. Expression of selected proteins in male germ cell development
Primordial 
germ cell Gonocyte Spermatocyte Spermatid
PLAP + + - -
c-Kit + + - -
Oct-3/4 + + - -
AP-2γ + + - -
PLAP; placental-like alkaline phosphatase, c-KIT; stem cell factor.
In addition to pluripotent factors, self-renewal factors may also contribute to the development 
of germ cell tumors. The polycomb group (PcG) member BMI-1 (B cell-specific Moloney mu-
rine leukaemia virus integration site 1) is involved in cell proliferation, stem cell renewal and 
human oncogenesis (Park et al. 2003). BMI-1 acts as proto-oncogene by down-regulating tu-
mor suppressor genes and it is found in various malignancies including neuroblastomas, breast 
cancer, lymphomas and epithelial tumors (Raaphorst 2005). Moreover, BMI-1 is expressed in 
epithelial ovarian cancer (Zhang et al. 2008a). BMI-1 cooperates with c-MYC and regulates 
self-renewal of stem cells and may thus be involved in tumorigenesis in germ cell tumors. 
1.3 Development and migration of germ cells
Primordial germ cells give rise to both types of gametes, oocytes and sperm cells. In mice 
PGCs originate from the proximal epiblast (adjacent to the extra-embryonic ectoderm) (Figure 
1E) (Lawson et al. 1994). The formation of PGCs is influenced by bone morphogenetic pro-
teins (BMPs). BMP-4 and BMP-8b are secreted by the extra-embryonic ectoderm and BMP-2 
by the extra-embryonic endoderm (Lawson et al. 1999, McLaren 2000, Ying et al. 2000). Thus, 
15
mouse embryos lacking bmp-4 or bmp-8b do not have any germ cells. 
In human development, between the 3rd and 4th week, a cluster of approximately 100 cells ap-
pears in the endoderm of the dorsal wall of the yolk sac near the allantois (Figure 1F). During 
the 4th and 5th weeks of development PGCs migrate from the extra-embryonic site via the yolk 
sac and the hindgut endoderm at the caudal end of the embryo, and via the dorsal mesentery of 
the hindgut to the genital ridges at the ventral sides of the mesonephros (Figure1G). The nature 
of this migration is under debate (Freeman 2003); it has been proposed to be active (amoe-
boid movements of PGCs) or passive (induced by growth-movements of the adjacent tissues). 
During the migration primordial germ cells proliferate and finally by the end of the 5th week or 
early in the 6th developmental week approximately 1000 PGCs reach the gonadal ridges. By the 
7th week of development the gonads have differentiated into testes or ovaries, and the migration 
of PGCs is completed. During the migration some PGCs might be stranded along the migration 
pathway. Thus, germ cell tumors might also appear outside of the gonads. 
Survival of the migrating PGCs is dependent on the interactions between these cells and the 
somatic cells along the migratory pathway. This interaction is mediated via the tyrosine kinase 
receptor c-KIT, expressed on the surface of PGCs, and its ligand, Kit ligand (stem cell factor), 
which is expressed in somatic cells (Fleischman 1993). In mammals, germ cells differentiate 
according to their somatic cell environment: XY germ cells can develop as oocytes in female 
embryos (Burgoyne et al. 1988). When germ cells enter ectopic sites such as the adrenal gland, 
they develop as oocytes even in male embryos (Zamboni et al. 1983). 
Dysgenetic gonads display an increased risk of germ cell tumors as a result of improper go-
nadal and germ cell maturation. Turner’s syndrome (45, X) patients are mainly infertile as a 
result of lack of oocytes, caused by massive loss of germ cells during childhood (Speed 1986). 
Oogonia are normally detected from the 18th gestational week and primordial follicles from the 
20th week. In contrast, in Turner’s syndrome embryos, only some oogonia and no primordial 
follicles are detected in fetal ovaries (Reynaud et al. 2004). Turner’s syndrome is also associ-
ated with an increased risk of germ cell tumors (Schoemaker et al. 2008).
Primordial germ cells in the ovary divide mitotically and transform into oogonia at the 9th week 
of development. The oogonia become surrounded by mesonephros-derived somatic cells, thus 
forming germ cell clusters. They undergo further DNA replication, thereafter entering meiosis 
and becoming oocytes. The oocytes develop into leptotene, zygotene and pachytene stages of 
meiotic prophase I before becoming arrested at the diplotene stage of meiosis I. This stage may 
be retained for up to 40–50 years until a follicle becomes atretic or develops into a full-grown 
follicle. In contrast to the ovary, primordial germ cells arriving at the testis are arrested in mito-
sis and further male gametogenesis is delayed until puberty. 
Oocytes reach their peak number of approximately 7 million during midgestation. The number 
of oocytes is already dramatically reduced by approximately 90 % at the time of birth. Whether 
or not a female will lose the capacity for oocyte production during embryogenesis or will retain 
the ability to produce oocytes later in life from potential PGCs within the ovary or at extrago-
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nadal sites remains a question of some controversy (Johnson et al. 2004, Byskov et al. 2005, 
Johnson et al. 2005).
 
2. Gonadal development
In humans bi-potential gonads arise as a paired structure within the intermediate mesoderm 
during the 4th week of development. This urogenital ridge region is located between the limb 
buds, filling most of the coelomic cavity. The bi-potential gonad is similar in female and male 
embryos until the 7th week of gestation. Thus, it can give rise to both testis and ovary. The uro-
genital ridge develops into three different sections: the pronephros, giving rise to the adrenals, 
the mesonephros, giving rise to the gonads, and the metanephros, giving rise to the kidneys. 
During the 6th week of development cells from the mesonephros and coelomic epithelium 
invade the mesenchyme in the region of the presumptive gonads to form aggregates of support-
ing cells, the primitive sex cords.
Intermediate mesoderm expresses various genes, including that for Wilms’ tumor suppressor 1 
(WT1) when developing into the bi-potential gonad (Figure 2). Later, WT1 is expressed in the 
developing Sertoli and granulosa cells (Hanley et al. 1999). WT1 activates other genes includ-
ing those for steroidogenic factor 1 (SF-1) and Antimüllerian hormone/Müllerian-inhibiting 
substance (AMH/MIS) (Nachtigal et al. 1998, Hossain et al. 2003). SF-1 regulates many genes 
including that for AMH/MIS (Shen et al. 1994, Ingraham et al. 2000). In addition, transcription 
of AMH/MIS is regulated by GATA-4 and its interaction with SF-1 (Viger et al. 1998, Trem-
blay et al. 1999). WT1 regulates Sex determining Region of the Y-chromosome (SRY) and 
AMH/MIS by binding and activating their gene promoters (Hossain et al. 2001, Hossain et al. 
2003, Matsuzawa-Watanabe et al. 2003). 
Steroidogenic factor 1 forms a link between SRY and the male developmental pathway and it 
is essential in the developing bi-potential gonad. Its expression is maintained in differentiating 
testis and it has a role in Sertoli and Leydig cell development (Hanley et al. 1999). In Sertoli 
cells SF1 acts in concert with Sox9, elevating AMH/MIS expression (Shen et al. 1994, Arango 
et al. 1999). In addition, SF-1 activates genes encoding the synthesis of testosterone in the 
Leydig cells. In humans, mutations in the SF-1 gene cause XY sex reversal, presenting with 
malformed fibrous gonads and fully developed Müllerian duct structures (Achermann et al. 
1999).
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Figure 2. Essential genes involved in gonadal differentiation. Solid line, activating effect; dashed line, inhib-
iting effect. Based on literature cited in section 2.
2.1 Ovarian differentiation 
Ovarian differentiation is less well understood than testicular differentiation. The discovery 
that gonads develop as ovaries in the absence of the Y-chromosome (or SRY gene) supports the 
view that the testicular pathway is the active pathway in gonadal development. Thus, ovarian 
differentiation has been thought to be a passive transformation in the absence of SRY. Howev-
er, some genes are now known to be essential for ovarian development (Figure 2). Mutations in 
genes including Wnt-4, rspo1, DAX1 and FOXL2, present complete or partial male sex reversal 
in mice and humans.  
In XX mice lacking Wnt-4 the ovary fails to form properly and its cells express testis-specific 
markers, including AMH- and testosterone-producing enzymes (Vainio et al. 1999). In Wnt-4-
deficient XX mice the Müllerian duct fails to develop and the Wolffian duct continues to de-
velop; thus the gonad has the appearance of a testis. However, the gonads do not form testicular 
cord structures or express Sertoli cell-specific markers. In humans, those with heterozygous 
Wnt-4 defects show Müllerian duct agenesis and signs of ovarian hyperandrogenism. 
Wnt-4 acts through the β-catenin pathway by causing stabilization of β-catenin and its entry 
into the nucleus. In the presence of Wnt, rspo1 also stabilizes β-catenin. Mice lacking rspo1 are 
characterized by a male phenotype similar to that in XX mice lacking Wnt-4 (Maatouk et al. 
2008). Humans with mutation in the R-SPONDIN1 (rspo1) gene display sex reversal (Parma et 
al. 2006). 
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In ovarian development Wnt-4 activates DAX1 (Dosage-dependent sex reversal; Adrenal 
hypoplasia congenital; X-chromosome) (Mizusaki et al. 2003). DAX1 plays a role in fe-
male gonadal development, as it appears to antagonize the functions of SRY and Sox9 and it 
down-regulates SF-1 expression (Nachtigal et al. 1998, Swain et al. 1998). In addition, DAX1 
reduces the synergy between GATA-4 and SF-1 (Nachtigal et al. 1998, Tremblay et al. 2001b) 
as well that between WT1 and SF-1 (Nachtigal et al. 1998). In the XX gonad, two ligands, 
Wnt-4 and rspo1, are capable of activating the β-catenin signalling pathway, and loss of either 
Wnt-4 or rspo1 in mice results in a partial sex-reversal (Vainio et al. 1999, Chassot et al. 2008, 
Tomizuka et al. 2008). Moreover, human XY subjects carrying duplication of both Wnt-4 and 
rspo1 show male-to-female sex reversal (Jordan et al. 2001). 
Another repressor of the male developmental pathway is FOXL2 (forkhead box L2). In hu-
mans, mutations in the FOXL2 gene display abnormal eye functions and premature ovarian 
failure, causing blepharophimosis/ptosis/epicanthus inversus syndrome (BPES) (Uhlenhaut et 
al. 2006). This syndrome is the only known autosomal dominant disorder to cause premature 
ovarian failure. In foxl2 -/- mice the ovaries transform after birth into seminiferous tubule-like 
structures with testosterone-producing Leydig cells (Ottolenghi et al. 2005). 
Migrating PGCs seem to play a more active role in ovarian development than they do in testis 
development. In the absence of PGCs, supporting cells in the ovary differentiate into prefollicle 
cells that aggregate into mesenchymal condensations, but these eventually degenerate, leaving 
only stromal tissue (Merchant-Larios et al. 1981). 
2.2 Testicular differentiation 
The formation of testicular cords is initiated between the 6th and 8th weeks of development.  
Once the PGCs have started their migration and entered the genital ridge during the 5th week 
they become enclosed by the differentiating Sertoli cells. Testis differentiation is induced by 
the expression of SRY (Sekido et al. 2009). SRY initiates the male pathway by triggering the 
differentiation of Sertoli cells in the genital ridge. The Sertoli cells become organized into cord 
structures that encircle immature germ cells (gonocytes). At the same time, in the interstitium 
of the testicular cords, Leydig cells differentiate and begin to secrete testosterone. Deregula-
tion of SRY expression can result in partial or complete failure of testis determination and the 
formation of ovotestes or ovaries within XY individuals. In humans, SRY mutations are found 
in 15 % of XY females (Hawkins et al. 1992a).
The transcription factors WT1 and SF-1 are able to bind and transactivate human SRY pro-
moters (Merchant-Larios et al. 1981) (Figure 2). Müllerian duct regression and Wolffian duct 
development is influenced by testosterone and by AMH produced by Sertoli cells. Production 
of AMH by fetal testicular Sertoli cells leads to initiation of irreversible Müllerian duct regres-
sion in the male fetus. Several transcription factors including SF-1, WT1, Sox-9 and GATA-4, 
regulate expression of AMH (Viger et al. 1998, Ingraham et al. 2000, Tremblay et al. 2001a, 
Hossain et al. 2003, Manuylov et al. 2007) (Figure 2).
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Bi-potential genital ridges will develop into the female phenotype unless influenced by tes-
tosterone and AMH. Absence of AMH in humans causes persistent Müllerian duct syndrome, 
a form of pseudohermaphroditism characterized by the retention of Müllerian duct structures 
(Josso et al. 2005). 
3. GATA transcription factors in gonadal development 
and physiology
GATA factors are a family of six zinc-finger transcription factors that recognize the consensus 
nucleotide sequence WGATAR (the GATA motif) in the promoter regions of target genes. Of 
the six GATA factors, GATA-4 and GATA-6 are essential in gonadal differentiation and in 
reproductive functions. GATA-4 and -6 are expressed in fetal developing and adult gonads. 
Gata4 -/- mice die as a result of defects in lateral folding and heart formation. Gata6 -/- mice 
die as a result of a gastrulation defect and the presence of underdeveloped visceral endoderm. 
Both of these GATA factors are essential for normal development of embryonal endoderm and 
extraembryonal endoderm forming visceral yolk sac (Soudais et al. 1995, Morrisey et al. 1998). 
GATA-4 is involved in testicular development, as it enhances AMH expression by 
directly binding to DNA and cooperatively interacting with SF-1 (Viger et al. 1998) 
(Figure 2). GATA-4 cooperates with SF-1 to activate AMH promoter-driven reporter 
gene activity in Sertoli cells in utero (Tremblay et al. 1999). In mice GATA-4, with its 
ability to interact with FOG-2, is essential for normal determination and differentiation 
of the gonad (Tevosian et al. 2002, Manuylov et al. 2008). In XY GATA-4-mutated 
homozygous mice, GATA-4 is not able to interact with FOG-2, and Fog-2-/- mice 
show similar defects in gonadal differentiation. In these mice, testicular cords do not 
develop, WT1 and SF-1 are not up-regulated, SRY expression is reduced, and Sox-9, 
AMH and steroidogenic enzymes are absent (Tevosian et al. 2002). Moreover, Wnt-4, 
a mediator of ovarian development, is not down-regulated.  
20
Figure 3. Expression of GATA-4, GATA-6 and FOG-2 in bi-potential and differentiated gonads. Based on the 
literature review in section 3 and the results of the present study. Black circles: primordial germ cells, white 
circles: Sertoli cells/granulosa cells, triangles: Leydig cells, squares: theca cells. 
In the human fetal ovary GATA-4 is expressed in pregranulosa/stromal cells (Figure 
3). At weeks 14 to 33, GATA-4 is localized in the ovarian granulosa cells, but it is not 
expressed in fetal oocytes (Vaskivuo et al. 2001). GATA-4 is possibly also involved 
in the survival of ovarian granulosa cells (Heikinheimo et al. 1997). Similarly as in 
the testis, GATA-4/FOG-2 interaction is essential in the ovary (Manuylov et al. 2008). 
Gata-4/Fog-2 mutants show a compromised female program in XX gonads. In the ab-
sence of GATA-4 interaction with FOG-2, expression of Wnt-4 and FOXL2 is lost, but 
rspo1 expression remains normal.  However, the loss of Gata-4/Fog-2 interaction does 
not affect germ cells, as they enter meiotic prophase normally (Manuylov et al. 2008). 
In human fetal testis the expression patterns of GATA-4 and GATA-6 partially overlap and they 
are localized mainly to the Sertoli and Leydig cells (Ketola et al. 2000). GATA-4 is expressed 
from the 12th week of gestation through to adulthood in these cells (Ketola et al. 2000). Expres-
sion of GATA-4 in Sertoli cells is strongest during the period of proliferation of these cells 
(weeks 19 to 22). In Leydig cells the expression is strongest during the periods associated with 
testosterone production (gestational week 15 and after puberty). In fetal and prepubertal germ 
cells GATA-4 expression is detected, but it is absent in germ cells after puberty (Ketola et al. 
2000). In addition, GATA-4 is expressed in Sertoli and Leydig cell tumors (Ketola et al. 2000).
GATA-6 is expressed in fetal testis during gestational weeks 16 to 40 (in the testicular cords 
and interstitium), with an expression peak during the second trimester (Ketola et al. 2003). It is 
localized to Sertoli and Leydig cells, with the strongest expression between gestational weeks 
16 to 23. Human fetal germ cells are devoid of GATA-6 (Ketola et al. 2003). 
The actions of GATA factors are modified by a number of co-activators and co-repressors. 
FOG-1 is expressed in hematopoietic cells, cooperating with GATA-1 in promoting cell dif-
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ferentiation (Tsang et al. 1997). FOG-2 was originally described as a cofactor of GATA-4 
(Tevosian et al. 1999). FOG-2 is expressed in developing mouse heart, the urogenital ridge, 
neuroepithelium, adult heart, brain and testis, and it interacts with all GATA factors, at least in 
vitro, either by activating or repressing, depending on cell type (Robert et al. 2002). FOG-2 and 
its interactions with GATA-4 are essential for heart morphogenesis and testicular development 
(Tevosian et al. 2000, Robert et al. 2002,).  
In mouse testis FOG-1 and FOG-2 are co-expressed with GATA-1, -4 and -6 in Sertoli and 
Leydig cells (Ketola et al. 2002, Robert et al. 2002). GATA-4/FOG-2 interaction is required 
for SRY expression, leading to gonadal differentiation and sex determination (Tevosian et al. 
2002). Thus, testicular development is hampered if their interaction is unable to occur as a 
result of gene manipulation leading to inability of FOG-2 to bind GATA-4. 
4. Estrogen receptors in gonadal development and 
physiology
Estrogen receptors are members of a large nuclear receptor superfamily of ligand-regulated 
DNA-binding transcription factors. In humans, a total of 48 nuclear receptors have been 
characterized, including estrogen, androgen, glucocorticoid, progesterone and thyroid hormone 
receptors. Lipophilic steroid hormones, including estrogens, bind to intracellular steroid recep-
tors. Ligand binding induces a conformational change in the steroid receptor and facilitates 
receptor dimerization, nuclear transport and interaction with target DNA motifs. Many synthet-
ic ligands have been designed to target these receptors pharmacologically, offering widespread 
clinical use. 
Estrogen actions are mediated via two estrogen receptors, ERα and ERβ (Green et al. 1986, 
Kuiper et al. 1996). The main ER ligand is 17β-estradiol and it binds equally well to both ERs. 
Estrogen action in a cell is the result of a balance between these two receptors. ERα often plays 
an activating role whereas ERβ plays a suppressive role.
 
The genes for these two receptors are located on different chromosomes. However, ERs show 
close similarity in their DNA-binding sites (97 % homology in amino acids) and less homology 
in their ligand-binding sites (55 % homology) (Kuiper et al. 1996, Mosselman et al. 1996). Es-
trogen receptors mediate their actions by ligand-dependent binding to the estrogen responsive 
elements (EREs) of target genes. 
Recent studies have revealed a novel rapid non-genomic pathway of estrogen action. One of 
the suggested receptors involved is GPR30. However, GPR30 knockout mice do not show any 
histological or functional variation in the main estrogen target tissues (ovary, breast and uterus) 
(Otto et al. 2009). 
Work on transgenic mice has provided insight into the role of ERs in the development and 
function of the reproductive tract. These receptors are not vital in the embryonic period, given 
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that ERα, ERβ and ERαβ knockout (ERKO) mice develop beyond the fetal stage. αERKO 
mice are infertile, with a hypoplastic uterus, ovaries with only a few granulosa cells and cystic 
hemorrhagic follicles (Lubahn et al. 1993, Couse et al. 1998). Thus, in αERKO mice corpora 
lutea do not form. βERKO female mice have reduced fertility, and anatomical findings include 
normal uterus, and ovaries with many atretic follicles and fewer corpora lutea than normal 
(Krege et al. 1998).  αβERKO female mice are also infertile, with hypoplastic uteri, and ova-
ries with seminiferous tubule-like structures similar to those in male mice (Couse et al. 1999). 
Moreover, mice lacking both ERs display elevated levels of Sox9 and AMH and undergo post-
natal sex reversal (Couse et al. 1999).
Several human tissues including breast, brain, cardiovascular system, bone and urogenital tract 
express ERs. ERα is the main subtype in the liver, mammary gland, kidney, heart, skeletal 
muscle and pituitary, whereas ERβ is the major type in the prostate and colon. The distribu-
tion of the two ERs in the reproductive organs is different according to tissue and cell type. 
Thus, ERα is dominantly expressed in the uterus and in the ovarian thecal and interstitial cells, 
whereas ERβ is the predominant form in the granulosa cells (Kuiper et al. 1996, Enmark et al. 
1997). In fetal ovaries expression of ERs is localized to the granulosa cells and oocytes from 
the 20th week of gestation onward, with ERβ being the predominant form (Vaskivuo et al. 
2005) (Figure 4). 
 
        
 
     
    
         
 	      
    
      
 	         





Figure 4. Expression of estrogen receptors (ERs) α and β in fetal and adult gonads. Based on the literature 
review in section 3 and the results of the present study. Black circles: primordial germ cells, white circles: 
Sertoli cells/granulosa cells, triangles: Leydig cells, squares: theca cells. 
In addition to normal tissues, differential expression of the two ERs is seen in various neo-
plasms. Decreased expression of ERβ mRNA and protein, and an increased ERα/ERβ ratio 
has been reported in various malignancies, including breast, ovary, colon and prostate cancer 
(Rutherford et al. 2000, Campbell-Thompson et al. 2001, Roger et al. 2001, Fixemer et al. 
23
2003). Most (90 %) malignant ovarian tumors are of epithelial origin. Of these epithelial ovar-
ian cancers, two thirds express estrogen receptors (Lindgren et al. 2004). In addition, granulosa 
cell tumors express ERs (Chu et al. 2000). Anti-estrogen therapy has resulted in only modest 
responses in cases of recurrent ovarian cancer, possibly because of the low levels of ERs in 
these cancers (Makar 2000). 
Estrogen receptors regulate transcriptional activation by binding to EREs of target genes. In 
addition, co-regulators modify steroid receptor actions, acting as co-activators or co-repressors 
in nuclear receptor-mediated transcription. Co-activators regulate nuclear receptor function in 
a variety of ways. Their role may change depending on the tissue and cell type. There are up to 
300 co-regulators and they have many roles in various diseases, e.g. cancer, metabolic syn-
dromes and inheritable syndromes (Lonard et al. 2007). 
Small nuclear ring finger protein 4 (SNURF/RNF4) can co-activate both androgen- and estro-
gen-dependent transcription by interacting directly with these receptors (Moilanen et al. 1998). 
SNURF is expressed in fetal murine male and female germ cells, Sertoli cells and granulosa 
cells (Hirvonen-Santti et al. 2003, Hirvonen-Santti et al. 2004). In addition, the expression of 
SNURF has been reported to be increased in murine ovaries treated with estradiol (Hirvonen-
Santti et al. 2004).  
5. Gonadal Germ Cell Tumors 
Gonadal germ cell tumors are found in both sexes. In addition, germ cell tumors may be locat-
ed in extra-gonadal sites (e.g. mediastinum, hypothalamic/supracellular region) due to improp-
er migration of primordial germ cells during embryogenesis. In the ovary malignant germ cell 
tumors are rare, accounting for 3–5 % of all ovarian malignancies. In contrast, more than 95 % 
of testicular tumors are of germ cell origin. The incidence of testicular cancer has doubled dur-
ing the past 40 years (Huyghe et al. 2003). An annual 3–6 % increase is seen among Caucasian 
males. The highest incidence worldwide is in Denmark (9.2/100 000) (Huyghe et al. 2003). 
Moreover, there is an approximately fivefold difference in testicular cancer incidence between 
white and black males in the US and in southern England (McGlynn et al. 2005). This varying 
incidence among ethnic groups provides evidence for a genetic etiology in testicular cancer. 
There is strong evidence of an inherited risk of testicular cancer, as shown by the increased risk 
of the disease among first-degree relatives (Hemminki et al. 2004). Along with genetic factors, 
environmental factors play a role in testicular germ cell tumor development, as shown among 
the offspring of Finnish immigrants in Sweden. The immigrants maintained their lower risk, 
but their offspring showed an incidence similar to that in the Swedish population (Montgomery 
et al. 2005). Environmental factors including endocrine-disrupting chemicals (xenoestrogens 
and antiandrogens) are hypothesized to be involved in testicular tumorigenesis. Organochlo-
rines, e.g. polychlorinated biphenyls (PCBs) show estrogenic and antiandrogenic activity. 
Moreover, elevated PCB levels have been associated with mothers of TGCT patients (Hardell 
et al. 2003). 
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The only characterized chromosomal abnormality in TGCTs is relative gain of the short arm of 
chromosome 12 (Looijenga et al. 1999). Overrepresentation of 12p may be related to invasive 
growth (Rosenberg et al. 2000). In addition, overrepresentation of chromosome arm 12p is 
seen in testicular CIS adjacent to overt testicular tumors but not in CIS cells without a tumor 
(Ottesen et al. 2003). In addition to testicular tumors, abnormalities in choromosome arm 12p 
are detected in 80 % of ovarian dysgerminomas (Cossu-Rocca et al. 2006). 
5.1 Germ cell tumor development
Gonadal germ cell tumors are suggested to develop from primordial germ cells during em-
bryogenesis in utero. Most testicular tumors develop from a common tumor precursor called 
testicular carcinoma in situ (CIS), also referred to as intratubular germ cell neoplasia (ITGCN) 
or testicular intraepithelial neoplasia (TIN). Developmental arrest in the differentiation of the 
early germ cell lineage is hypothesized to be the key pathogenic event leading to neoplastic 
transformation of a primordial germ cell or gonocyte into a CIS cell. CIS cells most likely de-
velop from fetal gonocytes in utero. They resemble primordial germ cells and fetal gonocytes 
morphologically, and they share overlapping expression of several proteins, e.g. Oct-3/4, AP-2γ 
and c-KIT (Rajpert-De Meyts et al. 2003, Hoei-Hansen et al. 2004, Pauls et al. 2005). Recent 
genome-wide gene expression studies have revealed more evidence of the origin of CIS from 
fetal germ cells (Skotheim et al. 2002, Almstrup et al. 2005). As exceptions, infantile germ cell 
tumors and spermatocytic seminomas do not originate from CIS cells. 
Table 3. Characteristics of malignant ovarian germ cell tumors (MOGCTs), and testicular cancer and CIS
MOGCTs Testicular cancer Testicular CIS




+ RPLND (Stage ≥II)
Orchidectomy 
(unilateral CIS)
Chemotherapy Stage I: -
Stage II-IV: 






Radiation therapy Dysgerminoma Seminoma Bilateral CIS 
Prognosis Stage I: >99 %
Stage ≥II: >75 %
Stage I: >99 %
Stage ≥II: 50-90 %
Cancer in 70 % in 
7 years
USO, unilateral salpingo-oophorectomy; BEP, bleomysin, etoposide, cisplatin; RPLND, Retroperitoneal 
lymph node dissection
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The gonads share common development early in embryogenesis. Thus, gonadal germ cell 
tumors display similarities in morphology, histology, treatment and prognosis (Table 3, Table 
4). In addition, the presence of a few families with both ovarian and testicular germ cell tumors 
suggests a possible genetic etiology (Galani et al. 2005). Germ cell tumors are derived from 
cells of the germ cell lineage in which maturation is blocked (Figure 5). Dysgenetic gonads are 
associated with improper maturation of germ cells, thus these patients have an increased risk 
of germ cell tumors. In dysgenetic gonads gonadoblastoma is considered as a counterpart for 
testicular CIS. The presence of Y-chromosome material in cases of Turner’s syndrome is as-
sociated with an increased risk of gonadoblastoma (Mancilla et al. 2003). Other risk factors of 
testicular germ cell tumors (TGCTs) are a previous contralateral testicular tumor, undescended 
testis, and testicular tumors among first-degree relatives (Dong et al. 2001, Bromen et al. 
2004). In addition, increased fetal exposure to maternal hormones, and low birth weight have 
been linked to TGCTs (Cook et al. 2008). Moreover, some postnatal characteristics have been 
associated with an increased risk of testicular cancer: early puberty, tallness, and subfertility 
(Doria-Rose et al. 2005, McGlynn et al. 2007). 
PGCs 
Oogonia Gonocytes 
Carcinoma in situ 
Seminoma 
Non-Seminoma 




(YST, IT, EC, Mixed) 
Figure 5. Origin of various histological subtypes of gonadal germ cell tumors. PGCs: primordial germ cells, 
YST: yolk sac tumor, IT: immature teratoma, EC: embryonal carcinoma
5.2 Testicular dysgenesis syndrome
Testicular cancer is associated with testicular dysgenesis syndrome (TDS). In TDS all three tes-
ticular cell lineages (Sertoli, Leydig, germ cell) show improper function or maturation (Skak-
kebaek et al. 2001). As a consequence, clinical manifestations of TDS include hypospadias, 
cryptorchidism, poor semen quality and increased risk of testicular cancer. The risk of a con-
tralateral TGCT is elevated in cases of undescended testis, thus supporting the theory of TDS 
being associated with testicular cancer (Moller et al. 1996). Neonatal or perinatal exposure to 
estrogens have been suggested as risk factors of TDS. The synthetic estrogenic drug diethylstil-
bestrol (DES) was formerly used during pregnancy to prevent abortions and other pregnancy-
related complications (Palmlund et al. 1993). Later, DES was found to be associated with an 
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increased risk of vaginal cancer in female offspring and testicular malformations, impaired 
sperm quality and testicular cancer in male offspring (Storgaard et al. 2006, Rubin 2007). 
5.3 Clinicopathological characteristics of gonadal germ cell tumors
Germ cell tumors are histologically a heterogeneous group of tumors (Figure 5, Table 4). The 
most common group in both the testis and the ovary is the germinoma group (ovarian dys-
germinomas/testicular seminomas). Tumors may also harbor a mixture of different subtypes. 
Bilateral ovarian germ cell tumors are uncommon, with the exception of 10–15 % of cases of 
dysgerminoma. In 5–10 % of cases of ovarian germ cell tumor, patients are diagnosed with a 
benign cystic teratoma adjacent to the malignant tumor or in the other ovary. The majority of 
ovarian germ cell tumor patients present with abdominal pain, which is associated with an ab-
dominal mass in most cases. In testicular cancer patients the most common symptom is a hard 
swelling within a testis, mostly without any pain. Gonadal germ cell tumor diagnosis is histo-
logical after the primary surgery. Most ovarian and testicular germ cell tumors are diagnosed as 
Stage I tumors. More advanced ovarian tumors metastasize by way of the peritoneal surface or 
by lymphatic spread, whereas hematogenous spread is more common in testicular cancer. The 
testicular precursor CIS is detected clinically by ultrasonography, often in connection with mi-
crolithiasis, and confirmed by surgical biopsy. The risk of testicular cancer among CIS patients 
is 70 % within 7 years (von der Maase et al. 1986). 
Table 4. Classification and relative incidence ( %) of malignant gonadal germ cell tumors.
Ovarian Testicular
Dysgerminoma/seminoma 




















5.4 Serum and tissue tumor markers
Elevated concentrations of serum tumor markers are of value in the diagnosis of germ cell 
tumors. The serum tumor markers α-fetoprotein (AFP) and the β subunit of human gonadotro-
pin (hCGβ) are virtually diagnostic of germ cell tumors. Levels of AFP are elevated in yolk sac 
tumors whereas hCGβ concentrations are elevated in cases of choriocarcinoma and embryonal 
carcinoma (Table 5). In addition, serum levels of lactate dehydrogenase (LDH) are elevated in 
connection with some of the tumors. The level of LDH is of limited sensitivity, specificity and 
positive predictive value (Venkitaraman et al. 2007). Concentrations of LDH are also elevated 
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in cases of hemolytic anemia, chronic liver disease, chronic pancreatitis, congestive heart fail-
ure, collagen-vascular disease and muscular dystrophy. Serum LDH is of value as a prognostic 
factor in the diagnosis of TGCTs, but there can be false-positive findings when used in follow-
up. A diagnostic tissue marker in CIS cells is placental-like alkaline phosphatase (PLAP) (Gi-
wercman et al. 1991). PLAP is normally synthesized by trophoblasts after the first trimester of 
pregnancy (Manivel et al. 1987). It is a marker of PGCs and it is also seen in human oogonia, 
but not in oocytes after birth, while its activity is lost just after germ cells enter meiosis (Stoop 
et al. 2005). However, the biological function of PLAP in CIS cells is unknown.
Pathohistological diagnosis of germ cell tumors is based on histological evaluation and distinc-
tive immunohistological markers (Table 6). Germinomas have a characteristic histological ap-
pearance with primitive germ cells resembling primordial germ cells separated by fibrous septa 
and infiltrated by lymphocytes (Ulbright 2005, Roth et al. 2006). Germinomas may contain 
syncytiotrophoblastic cells producing hCG. In some cases germinomas may be confused with 
YSTs or Sertoli cell tumors (Ulbright 2005, Ulbright 2008, Looijenga 2009).
Yolk sac tumors appear in a variety of histological patterns, most of them staining positively 
for AFP and containing hyaline globules, thick bands of basement membrane material and 
Schiller-Duvel bodies resembling fetal glomeruli (Roth et al. 2006). Solid forms of YSTs may 
be confused with DGs and clear cell adenocarcinomas and endometrioid carcinomas (Ulbright 
2008). 
Embryonal carcinomas are composed of groups of large primitive cells with overlapping nuclei 
and distinct cell borders resembling those of the embryonic disc (Roth et al 2006). Solid forms 
of EC may be confused with DGs or some variants of YSTs. Embryonal carcinomas stain posi-
tively for PLAP. 
Choriocarcinomas consist of cytotrophoblasts surrounded by syncytiotrophoblasts, thus stain-
ing positively for hCG, human placental lactogen, inhibin, and low molecular weight cytokera-
tin, and sometimes PLAP (Roth et al. 2006). 
Immature teratomas are composed of embryonic tissue, but some mature tissue may be present 
(Roth et al. 2006). Immaturity manifests predominantly as immature neuroepithelial tissue. Im-
mature teratomas are graded from 1 to 3 based on the amount of immature neuroepithelium. 
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Table 5. Serum tumor markers in malignant gonadal germ cell tumors. 



















Table 6. Immunohistochemical markers used in differential diagnosis of gonadal germ cell tumors. 
OCT3/4 c-KIT SOX2 SOX17 CD30 AFP hCG PLAP
Dysgerminoma/
Seminoma
+ +/- - + - - - +
Embryonal ca + +/- + - +/- - - +
Yolk sac tumor - +/- - - - + - +/-
Chorioca - - - - - - + +/-
Modified from Looijenga 2009. 
5.5 Treatment and survival of gonadal germ cell tumor patients
Surgical treatment of gonadal germ cell tumors is fertility-sparing unilateral oophorectomy or 
orchiectomy, even in advanced stages (Table 3). Earlier, before the introduction of combination 
chemotherapy, virtually all patients died of the disease. Currently, platinum-based combina-
tions are the standard treatment for patients with other than Stage I disease. BEP (bleomycin, 
etoposide, cisplatin) combination chemotherapy is the gold-standard treatment, both in ovarian 
and testicular germ cell tumors. Compared with the previously used PVB (cisplatin, vinblas-
tine, bleomycin) combination, BEP displays equal efficacy and less toxicity in testicular germ 
cell tumor patients. The POMB-ACE (cisplatin, oncovin-vincristine, methotrexate, bleomycin, 
actinomycin-D, cyclophosphamide, etoposide) combination has been used in advanced and ag-
gressive testicular cancer and in advanced ovarian germ cell tumors (Murugaesu et al. 2006).
Malignant gonadal germ cell tumors are curable diseases with survival rates exceeding 95 %. 
Prognostic factors of malignant ovarian germ cell tumors have been stage, amount of residual 
tumor, histological subtype and raised concentrations of serum tumor markers. In addition, the 
size of the tumor is prognostic in testicular cancer.
Given that the majority of germ cell tumor patients survive the disease, the long-term effects of 
the treatments are important as regards their effects on fertility and health. Potential complica-
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tions after chemotherapy include an increased risk of cardiovascular diseases, neurotoxicity, 
hearing dysfunction, renal failure and secondary malignancy. Acute nonlymphoblastic leuke-
mia is the most common secondary malignancy, being associated with a 0.9 % risk in testicular 
cancer patients (Boshoff et al. 1995). In a recent study, following conservative surgery, fertility 
was preserved in most patients with malignant ovarian germ cell tumors, given that 76 % 
achieved at least one pregnancy (Tangir et al. 2003). In testicular cancer patients, chemothera-
py is associated with temporary azoospermia (Lampe et al. 1997). However, fertility rates are 
30 % lower in testicular cancer patients than in the normal population (Fossa et al. 2000), thus, 
indicating presence of related testicular dysgenesis syndrome.  
Aims of the Study
The aim of this study was to identify novel diagnostic and prognostic tools for evaluation of 
malignant gonadal germ cell tumors. In addition, the aim was to further reveal the biology 
behind the formation and differentiation of germ cell tumors.
The specific aims of this study were:
1. To characterize the role of GATA factors, their cofactors, and their target genes in testicular 
and ovarian germ cell tumors.
2. To analyze expression of the pluripotency transcription factors AP-2γ and Oct-3/4 in ovarian 
germ cell tumors.
3. To reveal the role of the estrogen signalling pathway in ovarian germ cell tumors.
4. To provide further evidence of the fetal origin of testicular CIS and germ cell tumors.
5. To assess the prognostic value of serum concentrations of AFP, hCGβ and CA 125 in malig-
nant ovarian germ cell tumors. 
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Patients, Samples and Methods
1. Malignant ovarian germ cell tumor patients (I, II, III) 
Table 7. Summary concerning patients with malignant ovarian germ cell tumors (n = 30).
n  %
Mean age, years (± SD) 30.0 (± 4.9)
Mean follow-up time, months (range) 92 (2–205)
Histological distribution
      Dysgerminoma (DG)
      Immature teratoma (IT)
      Yolk sac tumor (YST)










       I






Stage I       
         USO
         TAH and/or BSO
         Chemotherapy (platinum/non-platinum)
Stage II-III
         USO
         TAH and/or BSO













* ‘Others’ included two embryonal carcinomas and one mixed type with DG and YST components. 
USO = unilateral salpingo-oophorectomy, TAH = total abdominal hysterectomy, BSO = bilateral salpingo-
oophorectomy
2. Tissue samples (I–V)
2.1. Human malignant ovarian germ cell tumor samples
Approval for the study was obtained from the Ethics Committee of the Department of Obstet-
rics and Gynecology, University of Helsinki, and from the National Authority for Medicolegal 
Affairs. Tumor samples (n = 14), originally collected for diagnostic purposes at the Department 
of Obstetrics and Gynecology, Helsinki University Central Hospital, between 1982 and 2002 
were used for the present study. 
2.2. Human fetal testicular, testicular CIS and tumor samples 
The Regional Committee for Medical Research Ethics in Denmark approved the use of ano-
nymised human tissue samples for gene expression studies. 
Ten normal fetal testicular samples (gestational weeks 15–41) were obtained from tissue 
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archives of the Department of Pathology, Rigshospitalet, Copenhagen, Denmark. The tissues 
had been stored after autopsy of material from induced or spontaneous abortions and stillbirths, 
mainly in connection with placental or maternal problems. Fetal age was estimated from the 
date of the last menstrual bleed, and the developmental stage was based on the foot size of 
the fetus. Specimens of testicular tumors and the adjacent tissue, which usually contains CIS, 
were obtained after orchidectomy performed for therapeutic purposes. The tissue sections were 
fixed in either buffered formalin or paraformaldehyde and subsequently embedded in paraffin. 
In total, 10 CIS and 11 tumor samples (6 seminomas and 5 non-seminomas) were analyzed by 
immunohistochemistry.
3. Human germinoma-derived cell line (II, III, V)
The NCC-IT human germinoma cell line (Teshima et al. 1988) was obtained from The Ameri-
can Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 
medium (Gibco, Invitrogen Corporation, Carlsbad, CA, USA) supplemented with fetal bovine 
serum (10 %) and penicillin-streptomycin (1 %).
4. Immunohistochemistry (I–IV) 
The primary antibodies used for immunohistochemistry are presented in Table 8. The anti-
SNURF antibody has been described previously (Hakli et al. 2005). The monoclonal antibody 
to AMH (MIS) was a gift from Dr. R. Cate (Biogen, Cambridge, MA, USA). The tissue sec-
tions from paraffin-embedded tissue blocks were deparaffinized and rehydrated using descend-
ing concentrations of ethanol. Antigen retrieval was performed by incubating the slides in 
0.1 M citric acid (pH 8.0) at approximately 100 °C for 20 min. Endogenous peroxidase activity 
was blocked with 3% H2O2 in water for 5 min. Incubation with the primary antibody was car-
ried out overnight at 4 °C. An avidin-biotin immunoperoxidase system was used to visualize 
bound antibody (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA, USA), with 
3,3’-diaminobenzidine (Sigma, St. Louis, MO, USA) or aminoethyl carbazole (Zymed, San 
Francisco, CA, USA) as chromogens. The sections were counterstained with hematoxylin. In 
negative control experiments PBS replaced the primary antibody. 
After immunohistochemical staining, sections were analyzed under a light microscope. Scoring 
of the antigens was based on the staining intensity of at least 10 % of the tumor cells. 
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Table 8. Antibodies used in immunohistochemistry.
Antibody Company Catalog# Host Dilution
AP-2γ Santa Cruz sc-12762 Monoclonal Mouse 1:200
BMP-2 Santa Cruz sc-6895 Polyclonal Goat 1:100
ERα DakoCytomation M7047 Monoclonal Mouse 1:50
ERβ AbD Serotec MCA1974S Monoclonal Mouse 1:50
FOG-2 Santa Cruz sc-10755 Polyclonal Rabbit 1:100
GATA-4 Santa Cruz sc-1237 Polyclonal Goat 1:200
GATA-6 Santa Cruz sc-9055 Polyclonal Rabbit 1:500
HNF-4 Santa Cruz sc-6566 Polyclonal Goat 1:200
Ihh Santa Cruz sc-1782 Polyclonal Goat 1:100
INHα AbD Serotec MCA951S Monoclonal Mouse 1:500
Oct-3/4 Santa Cruz sc-8629 Polyclonal Goat 1:1000
SF-1 ABR Affinity 
BioReagents
PA1-24565 Polyclonal Rabbit 1:2000
5. Western blotting (V)
Protein from cultured NCC-IT cells was extracted using a commercial NucleoSpin® RNA/
protein kit (Machery-Nagel, Düren, Germany). Total protein (5 µg) was separated by 7.5 % 
SDS-PAGE and transferred to PVDF membranes. Non-specific binding was blocked with 5 % 
nonfat milk in 0.1 % Tween-TBS buffer for 1 h. The membrane was incubated overnight with 
primary (AP-2γ) antibody, followed by secondary antibody and subsequent visualization by us-
ing Enhanced Chemiluminescence Plus Kits (Amersham Biosciences Inc., Arlington Heights, 
IL). Beta-actin was used as a loading control.
6. Semi-quantitative RT-PCR (III, V) 
Cells were collected at different time points (24–120 h) after stimulation, and total RNA was 
isolated using RNeasy kits (Qiagen, Hilden, Germany). Purified RNA (1 µg) was reverse-
transcribed and 2 µL of the reaction mixture was used for each PCR. The primers and thermal 
cycler conditions are presented in Table 9. The numbers of cycles used for PCRs were 32 for 
ERα, 32 for ERβ, 30 for SNURF, and 30 for β-actin. Agarose gel electrophoresis (2 %), run in 
the presence of SybrSafe™ DNA gel stain (Invitrogen, Carlsbad, CA, USA) demonstrated PCR 
products of expected size (Figure 2A, B) for each of the PCR primer pairs. Threshold cycles 
were normalized to those for β-actin. The intensities of the bands were analyzed by using the 
Bio-Rad Gel Doc program (Bio-Rad Laboratories, Hercules, CA, USA) and quantified by us-
ing Quantity One software (Bio-Rad Laboratories).
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AP-2γ 5’-gacgccatgttgtggaaaataacc-3’ 5’-gaaagtagggtggcggctgatatt-3’ 269 52
ERα 5’-ggagacatgagagctgccaac-3’ 5’-ccagcagcatgtcgaagatc-3’ 439 70
ERβ 5’-ggccgacaaggagttggt-3’ 5’-tccatgcccttgttactcg-3’ 519 70
SNURF 5’-tgactacccatactcccagaaacgcc-3’ 5’-gctgtctgtctgtccatccgtctctc-3’ 298 60
β-actin 5’-cgggaaatcgtgcgtgacattaag-3’ 5’-ttcgtggatgccacaggactcc-3’ 213 72
7. Stimulation of NCC-IT cells with estradiol (III)
The cells were plated on 12-well dishes at a density of 25 × 105 per well and incubated in 
RPMI-1640 (phenol red-free) supplemented (10 %) with dextran-charcoal-treated fetal bovine 
serum (HyClone, Logan, UT, USA) for 48 h before stimulation. NCC-IT cells were stimulated 
with 17β-estradiol (E2) (Sigma, St. Louis, MO, USA) at concentrations of 1 to 1000 nmol/L 
for 24–120 h to determine time- and dose-responses for the expression of ERs and their co-
activator SNURF. For control experiments, the anti-estrogen ICI 182,780 (Tocris Cookson Ltd., 
Bristol, UK) was added at a concentration of 1000 nmol/L simultaneously with 1 nM E2. The 
concentrations of E2 and anti-estrogen were based on those used in corresponding experiments 
by others (Martin et al. 2005). All incubations were performed in duplicate and repeated at least 
three times. Untreated and vehicle-only-treated controls were included in each experiment. 
8. Cell transfection and siRNA (V)
NCC-IT cells were plated on 6-well plates 24 hours prior to transfection. They were subse-
quently transfected with Lipofectamine 2000 as instructed by the supplier (Invitrogen). Control 
cells were untreated or treated with Lipofectamine 2000. AP-2γ siRNA (small interfering RNA) 
was purchased from Thermo Fisher Scientific Inc. (Dharmacon Inc., Chicago, IL, USA). Trans-
fection was performed for each experiment according to the supplier’s instructions, in antibiot-
ic-free media. The media were changed 4 hours after transfection. The cells were collected for 
RNA and protein analyses 24 hours after transfection. 
9. Flow cytometric analysis (III, V)
To analyze cell proliferation, an APC BrdU Flow Kit (BD Biosciences, San Jose, CA, USA) 
was used, following the staining protocol described by the manufacturer. After E2 or anti-
estrogen (ICI 182,780) stimulation, the cells were labelled with BrdU (an analog of the DNA 
precursor thymidine) at a concentration of 10µmol/L. Cells were harvested at different time 
points (6 to 48 h), fixed, and stained with an anti-BrdU-specific APC fluorochrome according 
to the manufacturer’s protocol. Cells with incorporated BrdU, indicating proliferating cells, 
were analyzed by flow cytometry (FACSAria, BD Biosciences).
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10. Statistical analysis (II, III)
The probability of survival was estimated by the Kaplan–Meier method. When analyzing over-
all and disease-specific survival, the event was death. Data collected after cell stimulation is 
expressed as mean ± SEM derived from three independent experiments, all with two replicates, 
and adjusted to a value of 1.0 for the mean of the first control culture. The E2 and ICI 182,780 
stimulation data were analyzed by using Student’s t test. A p value < 0.05 was considered 
statistically significant. The statistical software used was SPSS, versions 13.0–16.0 (SPSS Inc., 
Chicago, IL, USA).
Results and Discussion
1. Biology of gonadal germ cell tumors
1.1 Pluripotency and self-renewal in ovarian germ cell tumors (II, IV) 
The origin of germ cell tumors is suggested to be the early primordial germ cell. Primor-
dial germ cells resemble embryonic stem cells, which are characterized by pluripotency and 
self-renewal capacity. AP-2γ and Oct-3/4 play key roles in embryonic stem cell survival and 
pluripotency (Hansis et al. 2000, Pauls et al. 2005). Thus, it may be speculated that these fac-
tors also play roles in germ cell tumorigenesis. In the present work AP-2γ and Oct-3/4 were 
analyzed in the MOGCT samples and both of these factors were present in DGs but mostly 
absent in YSTs and ITs (Figure 6, Table 10) (II). Expression of these pluripotent markers sug-
gests that DGs represent primitive germ cell tumors. In contrast, pluripotency is lost in more 
differentiated MOGCT subtypes such as yolk sac tumors. The expression of these pluripotent 
markers in early fetal gonadal germ cells and in dysgerminomas may indicate that this tumor 
type originates from early fetal germ cells.
Table 10. Expression of markers of pluripotency (AP-2γ, Oct-3/4) vs. endodermal differentiation in malignant 
ovarian germ cell tumors. Based on the present study (I, II).
Markers of pluripotency Markers of endodermal differentiation






















In addition to the pluripotent factors Oct-3/4 and AP-2γ, self-renewal factors may also play 
a role in germ cell tumorigenesis. The protein BMI1 is involved in self-renewal of stem cells 
(Park et al. 2003). In mice BMI1 is expressed in undifferentiated spermatogonia and its over-
expression increases their proliferation (Zhang et al. 2008b). BMI1 is also expressed in human 
testicular germ and Sertoli cells (Sanchez-Beato et al. 2006). However, in testicular cancer 
BMI1 is expressed in only 30 % of the tumors (Sanchez-Beato et al. 2006). In contrast, in the 
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present study BMI1 was expressed in all histological subtypes of MOGCTs and in all samples 
(Figure 6) (unpublished results). Thus, the proto-oncogene BMI1 might play a role as a germ 
cell self-renewal factor, allowing malignant germ cell tumor development. 
Figure 6. Expression of AP-2γ, Oct-3/4 and BMI1 in ovarian dysgerminomas (left column A, C, E), and yolk 
sac tumors (right column B, D, F). Scale bar 200 µm, original magnification x10. Lines one and two are re-
printed from a publication in Tumor Biology (2008), Salonen et al., with permission from S. Karger AG, Basel 
(II). Line three presents unpublished data based on the present study.
1.2 CIS and fetal origin of testicular germ cell tumors (IV)
Carcinoma in situ cells represent the origin of most testicular germ cell tumors. These cells 
resemble fetal gonocytes and embryonic stem cells. GATA-4 is an essential transcription factor 
in testicular development. In the present study the role of GATA-4 was elucidated in fetal tes-
ticular cells and in testicular cancer precursor cells (IV). The present study confirmed GATA-4 
expression both in fetal and adult Sertoli and Leydig cells (IV). Similarly to its expression in 
somatic cells of the fetal testis, it is also expressed in fetal ovarian granulosa cells (Vaskivuo 
et al. 2001). A subset of early fetal testicular germ cells at the 15th gestational week expressed 
GATA-4 (Table 11, Figure 7) (IV). Of the early fetal gonocytes, 72–81 % expressed GATA-4. 
GATA-4 was not, however, expressed later in fetal or in adult germ cells (IV). In contrast to 
early fetal testicular gonocytes, fetal oocytes do not express GATA-4 (Vaskivuo et al. 2001).
These data indicate that GATA-4 may have a function in early fetal gonocyte development, 
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possibly in connection with their differentiation. In contrast to germ cells, in testicular Ser-
toli and Leydig cells GATA-4 has functions throughout fetal and adult life (IV). Similarly to 
GATA-4, GATA-6 was expressed in fetal Sertoli cells and in adult somatic cells (IV). However, 
GATA-6 was not found in testicular fetal and adult germ cells (IV). Thus, GATA-6 has a role 
only in testicular somatic cells but not in germ cell function. Taken together, although germ 
cells develop from similar primordial germ cells in both sexes, different transcription pathways 
are expressed in female and male germ lines during development. 
Figure 7. Expression of GATA-4 in fetal gonocytes (A) at the 15th gestational week (arrow 
heads) and (B) at the 20th gestational week. Expression of GATA-4 (C) and FOG-2 (D) in tes-
ticular CIS cells (arrow heads). Modified from Salonen et al., submitted (IV). 
Carcinoma in situ cells expressed GATA-4 in heterogeneous manner, with 24 to 93 % (mean 68 
%) of the cells showing positive expression of immunohistological staining. When present, the 
type of adjacent tumor (seminoma or non-seminoma) was not associated with the amount of 
GATA-4-positive CIS cells, although the lowest degree of positivity (24 %) was seen in a CIS 
specimen not adjacent to any tumor type. Thus, GATA-4 expression in early fetal gonocytes 
and its absence later in fetal and adult germ cells provide additional evidence that CIS cells 
originate from early fetal gonocytes. The developmental down-regulation of GATA-4 in germ 
cells is similar to AP-2γ down-regulation during fetal development. However, GATA-4 was 
already absent by the 17th gestational week (IV), in contrast to AP-2γ, which is down-regulated 
later (after the 22nd gestational week) (Hoei-Hansen et al. 2004). Thus, the present data pro-
vide further evidence of the very early development of CIS cells during the first 15 gestational 
weeks.
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Table 11. GATA-4 expression in fetal and adult testicular tissue. Based on the present study (IV).
FETAL
15th gest. week                     17th gest. week ADULT
Germ cell + - -
Sertoli cell + + +
Leydig cell + + +
1.3 Function of GATA-4 in fetal testicular and CIS cells (IV)
GATA-4 plays a role in testicular development. Thus, GATA-4 target genes as well as GATA-
4’s co-factor FOG-2 are essential in gonadal differentiation and hormonal regulation. In the 
present study, FOG-2 was expressed in fetal somatic Sertoli and Leydig cells (IV). In addi-
tion, the GATA-4 downstream target genes SF-1 and INHα were expressed in fetal as well as 
in adult somatic cells (IV), as expected (Rabinovici et al. 1991, Hanley et al. 1999). Another 
GATA-4 target gene, AMH, was expressed in fetal and immature Sertoli cells (IV), as also 
reported previously (Tilmann et al. 2002). Thus, GATA-4 may have different functions in vari-
ous testicular cells during different stages of development, as shown by differential expression 
of its target genes. In addition to GATA-4, AMH is regulated by SRY and Sox9 (Figure 2) (de 
Santa Barbara et al. 2000). Thus, besides GATA-4, additional upstream regulators of GATA-4 
target genes may play important roles during different developmental stages of gonadal devel-
opment.
Of the GATA-4 target genes, SF-1 was heterogeneously expressed in CIS cells. However, 
other GATA-4 target genes, AMH and INHα, were mostly negative in CIS specimens. Thus, in 
testicular CIS cells at least one of the GATA-4-regulated genes was expressed, supporting the 
concept of an active role for GATA-4 in driving target gene transcription in CIS cells. 
Given that interaction of GATA-4 and FOG-2 is essential in normal testicular development 
and function (Tevosian et al. 2002), their expression in CIS samples (90 %) provides evidence 
of the normal function of GATA-4 in these cells (Figure 7) (IV). In contrast, FOG-2 was 
expressed only in some of the seminomas (33 %), whereas GATA-4 protein was present in all 
studied seminomas (IV). There may well exist some unknown cofactors in addition to FOG-2 
functioning in these germ cell tumors in concert with GATA-4. It is plausible that GATA-4 
may not regulate its normal target genes during testicular tumor development, in the absence of 
FOG-2.  
Steroidogenic factor-1 is expressed in mouse primordial germ cells (Hinshelwood et al. 2005). 
In contrast, in the present study SF-1 was not expressed in human fetal gonocytes (IV). More-
over, SF-1 expression was absent in all non-seminomas and most seminomas, but it was ex-
pressed in CIS cells (IV). In normal fetal and adult Sertoli and Leydig cells SF-1 was expressed 
(IV). Thus, the expression of SF-1 in CIS cells and its absence in germ cells provide evidence 
of abnormal differentiation. CIS cells develop from primordial germ cells, but along with their 
development the normal gene expression pattern may be disturbed, as shown by the Sertoli 
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cell-like expression of SF-1.
1.4 Estrogen signalling pathway in MOGCTs (III, V)
It has been suggested that estrogens have a role in testicular germ cell tumorigenesis during 
embryogenesis (Toppari et al. 1996, Skakkebaek et al. 2001). We speculated that estrogens 
could also have a role in the formation of ovarian germ cell tumors. The peak incidence of 
MOGCTs occurs soon after puberty, thus activation of the pituitary-ovarian axis causing a 
steroid hormone burst may be hypothesized to stimulate the formation of these tumors. As 
ERα and ERβ are expressed in fetal oocytes (Vaskivuo et al. 2005), they may also be present 
in germ cell tumor precursor cells. In line with our hypothesis, both estrogen receptors were 
expressed in oocytes of normal ovaries and all MOGCT subtypes (III), providing the possibil-
ity of estrogen action in these tumors. 
Estrogen actions are modified by various co-regulators. SNURF is an ER co-activator and it is 
expressed in murine fetal and postnatal germ cells (Hirvonen-Santti et al. 2004). In the present 
study, expression of SNURF was localized to human oocytes and all MOGCT subtypes (III). 
Thus, by regulating steroid hormone action, SNURF may contribute to the transformation of 
an oocyte into a germ cell tumor. Ovarian dysgerminomas expressed SNURF (III), which is 
in contrast to the situation in a previously reported study of testicular seminomas, with nearly 
absent expression of SNURF (Hirvonen-Santti et al. 2003). Thus, the function of ERs may dif-
ferentially be altered by different co-regulators in various gonadal germ cell tumors. 
Estrogen receptor beta has been suggested to have a suppressive role in various tumors. In epi-
thelial ovarian cancer expression of ERβ is down-regulated, whereas that of the ERα is similar 
or increased when compared with normal ovary (Bardin et al. 2004). In the present study, 
the expression of ERβ was stronger than that of ERα in most of the MOGCTs (III). Thus, in 
contrast to epithelial ovarian cancer, ERβ may not play a suppressive role in germ cell tumori-
genesis (Lazennec et al. 2001). The putative effect of estrogens on the development of ovarian 
tumorigenesis may also depend on the age of the subject. The use of oral contraceptives in fer-
tile women has a protective effect against ovarian epithelial cancer, whereas in postmenopausal 
women the use of estrogen products may increase the risk of ovarian cancer (Rossing et al. 
2007, Lurie et al. 2008). In the case of germ cell tumors the possible effect of estrogen on pri-
mordial germ cells occurs early in life, maybe even during fetal life. Thus, estrogens may have 
a different role and effect on the young female gonad and germ cell tumorigenesis compared 
with epithelial ovarian cancer in elderly women.
To study the effects of estrogens on germ cell tumors in vitro, stimulation studies were per-
formed using the human germinoma-derived NCC-IT cell line. In line with the results on the 
tumor samples, both ERα and ERβ and their co-activator SNURF were expressed in NCC-IT 
cells (III). Stimulation of NCC-IT cells with estradiol increased the expression of both ERs 
(Figure 8) and the increased expression was counteracted by concomitant treatment with anti-
estrogen (III). However, E2 did not have an effect on proliferation of NCC-IT cells; nor did the 
anti-estrogen (III). This could be due to ERs counteracting the effects of each other. Similarly 
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as in murine ovaries (Hirvonen-Santti et al. 2004), SNURF expression was up-regulated in 
NCC-IT cells treated with estradiol in the present study (III). Thus, SNURF may play a role 
in the estrogen signalling pathway in germ cell tumors (Figure 8). In addition to its genomic 
actions, estradiol has more rapid non-genomic actions through membrane-mediated activation 
of extracellularly regulated kinase and protein kinase A, resulting in stimulation of proliferation 
of seminoma cells (Bouskine et al. 2008). Thus, also the non-genomic actions of estradiol may 
differ from one cell type to another. 
Figure 8. Effect of estradiol (10 nM) on the expression of ERα, ERβ and SNURF in NCC-IT cells after 24 to 
72 hours of treatment. The data are expressed as mean ± SEM derived from three independent experiments 
(* p < 0.05, ** p < 0.005, C: control). Reprinted from a publication in Molecular and Cellular Endocrinology 
(2009), Salonen et al., with permission from Elsevier (III).
Estrogen signalling has an effect on the expression of AP-2γ in breast and prostate cancer cells 
(Orso et al. 2004, Zhang et al. 2007). In breast cancer cells estrogen increases AP-2γ expres-
sion (Orso et al. 2004). In prostate cancer cells AP-2γ is an upstream regulator of ERβ (Zhang 
et al. 2007). Similarly, as with the expression of ERs and SNURF, the expression of AP-2γ in 
NCC-IT cells was enhanced in response to E2 treatment (unpublished data, Figure 9) (V). The 
data provide further evidence of estrogen-modulated regulation of AP-2γ in germinoma cells. 
siRNA-mediated knockdown of AP-2γ reduced its protein expression levels by approximately 
70  % (Figure 9) (V). Moreover, proliferation of germinoma cells was reduced by approximate-
ly 40 % following silencing of AP-2γ with siRNA (unpublished data) (V). Thus, estrogen sig-
nalling in germinoma cells may also act via the AP-2γ pathway. The estradiol peak at puberty 
can be speculated to up-regulate ERβ, and also AP-2γ, which is essential for primordial germ 
cell survival (Hoei-Hansen et al. 2004). Survival of primordial germ cells in turn may enable 
the formation of germ cell tumors. 
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Figure 9. A. Stimulation with estradiol increased the expression of AP-2γ mRNA in NCC-IT cells. B. Block-
ing of AP-2γ by siRNA in NCC-IT cells had an effect on its protein expression as analyzed by Western blot. 
Analysis of the intensity of the bands was based on visual evaluation. C: control, Tr: transfection vehicle 
control. Based on the present study (unpublished data; V).
2. Diagnosis and prognosis of gonadal germ cell tumors
2.1 Diagnostic tools for gonadal germ cell tumors (I, II, IV)
Preoperative diagnosis of gonadal germ cell tumors is based on clinical findings, imaging 
studies (ultrasonography) and assay of serum tumor markers. Final histopathological diagnosis 
is made by morphological examination of the tumor after primary surgery. Gonadal germ cell 
tumors typically occur among young males and females; thus a germ cell tumor is to be consid-
ered in differential diagnosis in the case of a young patient presenting with suspected gonadal 
tumor. The serum tumor markers AFP and hCGβ are of value in diagnosis of the various germ 
cell tumor subtypes (Gershenson 1993). Concentrations of AFP are elevated mainly in cases 
of yolk sac tumors, whereas those of hCGβ are elevated in patients with choriocarcinomas 
and embryonal carcinomas. In the present study levels of serum AFP were elevated in half and 
those of hCGβ in one third of the MOGCT patients (II). In concordance with previous data, 
AFP levels were elevated in yolk sac tumor patients, whereas hCGβ levels were abnormally 
high in embryonal carcinoma patients (II). 
Serum concentrations of the commonly used marker in cases of epithelial ovarian cancer, CA 
125, were elevated in more than half of the MOGCT patients (II). In a previous study levels of 
CA 125 were elevated in 40 % of MOGCT patients (Deligeoroglou et al. 2004). In the present 
study, CA 125 levels were elevated in the majority of the yolk sac tumor (67 %) and immature 
teratoma (60 %) patients, but in fewer than half of the dysgerminoma (43 %) patients (II). 
Assay of CA 125 is probably not of value in the differential diagnosis of malignant ovarian 
tumors given that its levels are also elevated in cases of the more common epithelial ovarian 
cancer as well as in some noncancerous gynecological conditions such as pregnancy, endo-
metriosis, pelvic inflammatory disease and some diseases resulting in the presence of ascites 
(Halila et al. 1986, Halila et al. 1988, Perkins et al. 2003). 
Most of the tumors associated with elevated serum CA 125 concentrations also expressed CA 
125 antigen in the tumor tissue (II). However, some tumor samples collected from patients with 
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increased serum CA 125 levels did not reveal any immunohistochemically detectable CA 125 
(II). Thus, the lack of CA 125 expression in tumor tissues despite positive serum findings sug-
gests that sources other than the tumor itself, such as the peritoneal mesothelial cells, may be 
responsible for the secretion of CA 125 into the circulation, as a non-specific reaction to tumor 
growth.  
In addition to serum markers, tissue markers were evaluated. Similarly to what has been report-
ed previously (Cheng et al. 2004), we found that immunohistochemical detection of Oct-3/4 
was typical of dysgerminomas (Table 10) (II). In addition, another marker of pluripotency, 
AP-2γ, was specific for DGs (Figure 6, Table 10) (II). Thus immunohistochemical expression 
of Oct-3/4 and AP-2γ may be used for differential diagnosis of MOGCTs. 
Markers specific for endodermal differentiation, including GATA-4, GATA-6, HNF-4, BMP-2 
and Ihh, were all expressed in ovarian yolk sac tumors (I). In addition, GATA-4 was also 
expressed in DGs (Table 10) (I). GATA-4 and GATA-6 are essential factors in normal yolk sac 
development, and the present results, therefore, suggest that YST cells have maintained capac-
ity of GATA-4 and GATA-6 production. Given that GATA-6 and HNF-4 were present only in 
yolk sac tumors (I), they could be of value in histological diagnosis of this germ cell tumor 
subtype.  
Testicular seminomas and ovarian dysgerminomas are considered to be counterparts. In line 
with the expression of GATA-4 in ovarian DGs, testicular seminomas expressed GATA-4 
(Table 12) (IV). In contrast, ovarian DGs were GATA-6-negative, whereas most of the tes-
ticular seminomas (67  %) were GATA-6-positive (I, IV). In addition, GATA-6 was absent 
in all non-seminomas (IV). This data on the differential expression of the transcription factor 
GATA-6 in ovarian DGs and testicular seminomas provides evidence of variation in the tran-
scriptional pathways in these tumors, although they have been considered to be close female-
male counterparts.
In contrast to testicular seminomas and immature teratomas, embryonal carcinomas were total-
ly devoid of detectable expression of GATA-4 (IV). Moreover, none of the target genes (AMH, 
SF-1, INH-α) were expressed in embryonal carcinomas, nor were GATA-6 or FOG-2 (IV).
Table 12. Comparison of GATA-4, GATA-6 and FOG-2 expression in ovarian and testicular germ cell tumors 
as detected by immunohistochemistry. Based on the present study (I, IV).
GATA-4 FOG-2 GATA-6
Dysgerminoma +/- - -
Seminoma +/- +/- +/-
Yolk sac tumor (ov) + - +
Embryonal ca (te) - - -
Immature teratoma (ov) + + +
Immature teratoma (te) +/- +/- +/-
ov, ovarian; te, testicular 
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2.2 Prognostic tools for malignant ovarian germ cell tumors (II)
 
Since the introduction of platinum-based combination chemotherapy, MOGCTs have changed 
dramatically from deadly to curable disease. Currently, the 5-year survival rate approaches 100 
% (Pectasides et al. 2008). Among the present subjects, survival was somewhat lower (73 %) 
than in other recent studies (Table 13) (II). This could be a result of the low number of patients 
studied. In addition, in the present study the mean age of the patients was somewhat higher 
than in previous studies (II), thus possibly affecting the overall survival rate. However, differ-
ent histological subclasses show some variation as regards survival rate, YSTs being associated 
with modest survival. In the present study, patients with DGs had the highest survival rate (II), 
in line with the results of previous studies (Table 13). 
The main prognostic factors as regards ovarian germ cell tumors have been histological type, 
surgical stage and the presence of residual tumor tissue (Mitchell et al. 1999, Nawa et al. 2001, 
Lai et al. 2005). Levels of the serum tumor markers AFP and hCGβ are often elevated in pa-
tients with MOGCTs. AFP and hCGβ cannot be used as prognostic markers for all subtypes of 
MOGCTs, given their specificity to yolk sac tumors and choriocarcinomas, respectively. How-
ever, elevated levels of serum AFP and hCGβ have prognostic value in some cases of MOGCTs 
as assessed by univariate and multivariate analyses in a recent study (Murugaesu et al. 2006). 
Given that levels of AFP are elevated mostly in yolk sac tumors, a remarkably elevated AFP 
concentration (> 1000 kU/L) has had prognostic value in some studies (Mitchell et al. 1999, 
Nawa et al. 2001). In the present study the AFP level did not have a prognostic value (II), and 
others have reported similar findings (Mayordomo et al. 1994). The serum tumor marker CA 
125 is associated with epithelial ovarian cancer and the preoperative serum CA 125 concentra-
tion is an independent prognostic factor (Cooper et al. 2002). In the present study 56 % of the 
MOGCT patients had elevated serum CA 125 levels (II). Moreover, increased preoperative 
serum CA 125 values were associated with poor prognosis (Figure 10) (II). 
Figure 10. Kaplan–Meier analysis of probability of survival of MOGCT patients. A. Normal vs. elevated pre-
operative serum levels of CA 125 (p < 0.05). B. Age < 30 vs. age ≥ 30 years (p < 0.05). Left figure reprinted 
from a publication in Tumor Biology (2008), Salonen et al., with permission from S. Karger AG, Basel (II).
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In addition to an elevated serum CA 125 concentration, presence of residual tumor was as-
sociated with poor prognosis (II). The same observation has also been reported earlier (Lai et 
al. 2005). Also patients over 30 years of age had a more adverse outcome in the present study 
(Figure 9) (II). In contrast, age has not been a significant factor in some previous studies (Nawa 
et al. 2001). Most MOGCT patients are adolescents or young adults. In the present study the 
mean age (30.0 ± 4.9 [SD] years) of the patients was higher than in previous studies (Murugae-
su et al. 2006) (II); thus the older age of the patients may explain the somewhat poorer progno-
sis seen among the present subjects. 
Even though most MOGCT patients survive the disease, some patients still succumb to the 
malignancy. Novel prognostic markers may be of value in the identification of patients with 
more adverse outcome, so as to provide them with extended follow-up and/or non-traditional 
treatment modalities, e.g. high-dose chemotherapy, which has been used previously in cases of 
ovarian yolk sac tumors, with improved outcome (Kang et al. 2008). 
Table 12. Comparison of recently reported series of patients with malignant ovarian germ cell tumors.
FU = follow-up, SU = overall survival, DG = dysgerminoma, IT = immature teratoma, YST = yolk sac tumor, 
MIX/OTH = mixed or other, USO = unilateral salpingo-oophorectomy, RT = residual tumor, NDA = no data 
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3. Clinical significance of the studies
Patients with malignant gonadal germ cell tumors are commonly young women and men. 
Treatment and prognosis of these tumors are strikingly different in comparison with other 
gonadal malignancies. This study was carried out to shed further light on the molecular basis of 
these tumors, and to improve the diagnosis and follow-up of these patients. One of the specific 
aims was to define novel diagnostic and prognostic markers of MOGCTs. In addition, new 
molecular pathways of potential importance in germ cell tumorigenesis were assessed. The data 
are ultimately needed also in the development of  future therapies.
Conclusions and Future Perspectives
1.1 Conclusions
1. The expression of endodermal markers, the transcription factors GATA-4 and GATA-6, their 
cofactors and target genes was characterized in gonadal germ cell tumors. In ovarian germ 
cell tumors GATA-4 was expressed in dysgerminomas and yolk sac tumors, whereas GATA-6 
was expressed only in yolk sac tumors. In addition, downstream endodermal target genes of 
GATA-4 HNF-4, BMP-2 and Ihh were expressed in yolk sac tumors, but were mostly absent 
in dysgerminomas. Seminomas, the testicular counterparts of dysgerminomas, also expressed 
GATA-4. In contrast to dysgerminomas, most of the seminomas also expressed GATA-6. 
Although gonadal germ cell tumors share some characteristics, these tumors are different as 
regards expression of some of the transcription factors possibly playing important roles in the 
formation and maintenance of different germ cell tumors. 
2. Markers of pluripotency, AP-2γ and Oct-3/4, were specifically expressed in dysgerminomas, 
but were mainly absent from other types of ovarian germ cell tumor. Thus, they may be used as 
additional tools in the differential diagnosis of germ cell tumors. The expression of these mark-
ers provides also evidence of the pluripotent nature of dysgerminomas compared with other 
more differentiated germ cell tumor subtypes.
3. Both estrogen receptors (ERα and ERβ) and their co-activator SNURF were expressed in all 
ovarian germ cell tumor subtypes. Moreover, the human germinoma-derived cell line NCC-
IT expressed both ERs and SNURF. Also estradiol treatment up-regulated mRNA expression 
of ERs and SNURF in these cells, effect which was counteracted by the anti-estrogen ICI 
182,780. Collectively, the data suggest that estrogen signalling pathways may have roles in 
ovarian germ cell tumorigenesis.
4. In the testis, GATA-4 was expressed in early fetal germ cells at the 15th gestational week, 
being absent later in gestation and in adult germ cells. This transcription factor was also present 
in most of the premalignant CIS cells. GATA-4 was also expressed in testicular seminomas, 
but it was absent in embryonal carcinomas – tumors that have lost the germ cell phenotype. 
These findings suggest a role of GATA-4 in fetal germ cell differentiation, and they support the 
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concept of a fetal origin of testicular CIS cells. 
5. Elevated preoperative levels of the serum tumor marker CA 125 were associated with 
adverse outcome in patients with malignant ovarian germ cell tumors. Assay of serum CA 125 
provides a new tool for the evaluation and follow-up of patients with malignant ovarian germ 
cell tumors.
1.2 Future perspectives
Risk factors connected to ovarian germ cell tumors are still poorly understood. Epidemiologi-
cal studies of ovarian germ cell tumors could be used to reveal novel risk factors. It would also 
be interesting to compare the female and male counterparts of gonadal germ cell tumors, i.e. 
dysgerminomas and seminomas, as regards epidemiological data as well as various underlying 
and associated conditions.
Estrogen pathways may play a role in the development of germ cell tumors. Given that vari-
ous ER co-regulators modify ER actions, while the affinity for estradiol is equal, ERα- and 
ERβ-specific co-activators may be of interest, revealing possibly differential outcomes in the 
proliferation of germ cell tumors. Given that ERα and ERβ have different and opposite roles 
in estrogen signalling, it would be of great interest to study the possibly different roles of these 
receptors in germ cell tumors by using siRNA silencing of the gene products. 
Various genes are involved in gonadal differentiation. GATA-4 is involved in testicular dif-
ferentiation and function and it is expressed in germ cell tumors. Genes involved in ovarian 
differentiation such as WNT4 , DAX1, FOXL2, RSPO1 could also play roles in gonadal germ 
cell tumor development, and their expression in these neoplasms should be studied. 
To understand the causes behind germ cell tumors we need to learn more about factors in-
volved in germ cell development, differentiation and migration. In future, iPS cells may 
provide tools for experimental models of germ cell tumors in vitro, revealing novel molecular 
pathways in normal embryogenesis and in addition, in tumorigenesis. However, germ cell 
tumor development is a combination of genetic, molecular and environmental factors. Thus, 
we should connect basic molecular studies and epidemiological studies in future to provide 
further evidence of germ cell tumor development, and the data may later lead to possible novel 
therapeutics and prevention of these tumors. 
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